Literature DB >> 9762887

Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma.

S Burrow1, I L Andrulis, M Pollak, R S Bell.   

Abstract

BACKGROUND AND OBJECTIVES: We have previously shown that insulin-like growth factor (IGF)-responsive murine sarcomas demonstrate inhibition of local and metastatic disease growth when implanted in an IGF-deficient host animal. In this experiment, we tested whether IGF receptor (IGF-R) and ligands were expressed in human primary and metastatic osteosarcomas.
METHODS: Fifty-two specimens of human osteosarcoma tumor from 48 patients were assayed for IGF-R, IGF-1, and IGF-2 using reverse transcriptase polymerase chain reaction.
RESULTS: Twenty-one of 46 tumors analyzed had levels of expression of IGF-R greater than or equal to the positive control cell line. Twenty-seven of 44 expressed levels of IGF-1 greater than or equal to the positive control, as did 21 of 38 cases assayed for IGF-2. No differences were found between 40 primary tumor samples and 12 metastatic lesions in mean levels of IGF-R, IGF-1, or IGF-2. There was a moderately strong correlation between expression of IGF-R and IGF-1, suggesting that autocrine stimulation may be an important mechanism for stimulation of osteosarcoma proliferation.
CONCLUSIONS: A significant proportion of osteosarcoma tumors express IGF-R and ligands. Higher levels of expression were not correlated with metastatic lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9762887     DOI: 10.1002/(sici)1096-9098(199809)69:1<21::aid-jso5>3.0.co;2-m

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  40 in total

Review 1.  Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.

Authors:  Patrick J Messerschmitt; Ashley N Rettew; Robert E Brookover; Ryan M Garcia; Patrick J Getty; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2008-07-08       Impact factor: 4.176

Review 2.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

3.  Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study.

Authors:  Scott C Borinstein; Donald A Barkauskas; Mark Bernstein; Allen Goorin; Richard Gorlick; Mark Krailo; Cindy L Schwartz; Leonard H Wexler; Jeffrey A Toretsky
Journal:  Pediatr Blood Cancer       Date:  2013-10-31       Impact factor: 3.167

Review 4.  Antineoplastic effects of mammalian target of rapamycine inhibitors.

Authors:  Maurizio Salvadori
Journal:  World J Transplant       Date:  2012-10-24

5.  Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.

Authors:  Aleksandra Bielen; Lara Perryman; Gary M Box; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Alexa Jury; Sergey Popov; Sharon Gowan; Sebastien Jeay; Florence I Raynaud; Francesco Hofmann; Darren Hargrave; Suzanne A Eccles; Chris Jones
Journal:  Mol Cancer Ther       Date:  2011-06-09       Impact factor: 6.261

6.  Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Authors:  Swati Sikaria; Josefine Heim-Hall; Elizabeth H Diaz; Ronald Williams; Kamelesh Sankhala; Brenda Laabs; Monica Mita
Journal:  Target Oncol       Date:  2013-02-21       Impact factor: 4.493

7.  Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.

Authors:  Dhong Hyun Lee; Nils H Thoennissen; Catherine Goff; Gabriela B Iwanski; Charles Forscher; Ngan B Doan; Jonathan W Said; H Phillip Koeffler
Journal:  Cancer Lett       Date:  2011-03-26       Impact factor: 8.679

8.  Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Addy C M van de Luijtgaarden; Janneke D M Molkenboer-Kuenen; Sandra Heskamp; Melissa H S Roeffen; Hanneke W M van Laarhoven; Peter J Houghton; Wim J G Oyen; Otto C Boerman; Winette T A van der Graaf
Journal:  Clin Cancer Res       Date:  2011-10-28       Impact factor: 12.531

Review 9.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

10.  The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs).

Authors:  Maria A Pantaleo; Annalisa Astolfi; Margherita Nannini; Guido Biasco
Journal:  J Transl Med       Date:  2010-11-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.